| P2093 | author name string | Karen Dybkær | |
| | Paw Jensen | |
| | Hanne Due | |
| | Jakob Madsen | |
| | Marie Lindhard Madsen | |
| | Niels Ejskjær | |
| P2860 | cites work | Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine | Q67574342 |
| | Vincristine neurotoxicity with residual equinocavus deformity in children with acute leukemia | Q70896303 |
| | Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas | Q72399612 |
| | Block of axoplasmic transportin vitro by vinca alkaloids | Q72612008 |
| | Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma | Q75275328 |
| | Chemotherapy-induced peripheral neuropathy | Q77944571 |
| | Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients | Q80214224 |
| | The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20 | Q81776925 |
| | Chemotherapy-induced peripheral neuropathy in pediatric cancer patients | Q84234849 |
| | Vincristine-Induced Neuropathy Presenting as Ptosis and Ophthalmoplegia in a 2-Year-Old Boy | Q85597493 |
| | Vincristine-induced neuropathy: Atypical electrophysiological patterns in children | Q86902057 |
| | Serum alpha tocopherol, vitamin B12, and folate levels in childhood acute lymphoblastic leukemia survivors with and without neuropathy | Q87947590 |
| | Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience | Q88715577 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 |
| | Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia | Q28245060 |
| | A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy | Q28326902 |
| | High incidence of vincristine-induced neuropathy in lymphomas | Q28331786 |
| | Vincristine revisited | Q28374641 |
| | Reporting results of cancer treatment | Q29620070 |
| | Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature. | Q31140346 |
| | Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma | Q33180146 |
| | Selective metabolism of vincristine in vitro by CYP3A5. | Q33242594 |
| | Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy | Q33688318 |
| | Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial | Q33701381 |
| | Effects of the antifungal agents on oxidative drug metabolism: clinical relevance | Q33858325 |
| | Interaction of common azole antifungals with P glycoprotein | Q34104641 |
| | Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia | Q34486506 |
| | Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies | Q34788181 |
| | Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study | Q35101236 |
| | Neuropathic pain during treatment for childhood acute lymphoblastic leukemia | Q35106072 |
| | Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia | Q35225760 |
| | Guillain-Barre syndrome in acute lymphoblastic leukemia: Causal or coincidental | Q35401316 |
| | Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer | Q35513996 |
| | Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia | Q35616085 |
| | Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia | Q35754431 |
| | Ancestry and pharmacogenetics of antileukemic drug toxicity | Q35828717 |
| | Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia | Q36176588 |
| | Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention | Q36344699 |
| | Patient-reported outcomes and the evolution of adverse event reporting in oncology | Q36996994 |
| | Effects of antimitotic agents on tubulin-nucleotide interactions | Q37053573 |
| | Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma | Q46672089 |
| | Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression | Q46906576 |
| | Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. | Q47177557 |
| | Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. | Q47310338 |
| | Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population | Q47358258 |
| | Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy | Q47552411 |
| | CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia | Q47778081 |
| | Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. | Q48111780 |
| | Neurotoxicity of vincristine on the medial olivocochlear bundle | Q48403635 |
| | Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report | Q48542836 |
| | Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration | Q48647898 |
| | Small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia | Q49361277 |
| | Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population. | Q50897138 |
| | Nerve lesions after therapy for childhood acute lymphoblastic leukemia. | Q50914341 |
| | Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. | Q51028561 |
| | Burden of chemotherapy-induced neuropathy--a cross-sectional study. | Q51743346 |
| | Vincristine toxicity with co-administration of fluconazole during induction therapy for pediatric acute lymphoblastic leukemia. | Q52780226 |
| | Vincristine induced cranial polyneuropathy. | Q53614005 |
| | Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome? | Q58794709 |
| | The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale | Q58874455 |
| | Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. | Q64898627 |
| | Optic Neuropathy Presumably Caused by Vincristine Therapy | Q67437299 |
| | Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia | Q37398949 |
| | Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia | Q37632970 |
| | Vincristine-induced vocal cord palsy: case report and review of the literature | Q37761023 |
| | Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma | Q38014151 |
| | Vincristine-induced blindness: a case report and review of literature | Q38264883 |
| | Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials | Q38716340 |
| | Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. | Q38796874 |
| | Electrophysiological Studies to Detect Peripheral Neuropathy in Children Treated With Vincristine. | Q38855837 |
| | The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia | Q39115111 |
| | An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia | Q39401025 |
| | Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. | Q39957258 |
| | Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity | Q40353990 |
| | Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia | Q40358186 |
| | Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer | Q40605146 |
| | Neurotoxicity of antineoplastic agents | Q40847058 |
| | Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma | Q41264440 |
| | Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy | Q42198365 |
| | Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone | Q42232097 |
| | Can severe vincristine neurotoxicity be prevented? | Q42241620 |
| | Syndrome of inappropriate secretion of antidiuretic hormone caused by vincristine therapy: a case report of the neuropathology | Q42243549 |
| | Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex | Q42244573 |
| | Acute acoustic nerve palsy associated with vincristine therapy | Q42269167 |
| | Oculomotor nerve palsy associated with vincristine treatment | Q42275082 |
| | Long-term effects of vincristine on the peripheral nervous system | Q42288782 |
| | Clinical neurological findings of children with acute lymphoblastic leukaemia at diagnosis and during treatment | Q42289406 |
| | Severe vincristine toxicity in combination with itraconazole | Q42540797 |
| | Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine | Q42556661 |
| | Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. | Q42557843 |
| | A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study. | Q42870077 |
| | Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis | Q42948863 |
| | Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy | Q43039563 |
| | Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma | Q43073865 |
| | Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma | Q43108162 |
| | Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: Case report and review of the literature | Q43157487 |
| | Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children | Q43495818 |
| | Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. | Q43791316 |
| | Risk of diabetes associated with prescribed glucocorticoids in a large population | Q43828487 |
| | Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics | Q44301929 |
| | Acute sixth-nerve palsy after vincristine therapy | Q44768732 |
| | Isolated abducens nerve palsy induced by vincristine therapy | Q44768734 |
| | Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen | Q44800298 |
| | The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. | Q45350320 |
| | Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia | Q45402986 |
| | Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening | Q46395878 |
| | CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer | Q46455283 |
| | Vincristine-induced urinary bladder paralysis | Q46488460 |
| P433 | issue | 3 | |
| P921 | main subject | vincristine | Q408977 |
| | systematic review | Q1504425 |
| P304 | page(s) | 471-485 | |
| P577 | publication date | 2019-06-18 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review | |
| P478 | volume | 84 | |